Published on December 10, 2010
Innovotech Inc.Pursuing the Greatest Opportunityin Microbiology Since Penicillin
On the Radar
1 December 2010
Forward Looking Statements This presentation contains forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Forward-looking statements may include words such as “expects”, “plans”, “will”, “believes”, “estimates”, “intends”, “may”, and other words of similar meaning and may relate to future financial performance, business strategies, or safety and efficacy of unapproved products. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; the demand for new products and the impact of competitive products, service and pricing; availability and cost of raw materials; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defence; the Company’s exposure to lawsuits and other matters beyond the control of management.
Opportunity BiofilmsThe natural state of bacteriaPlaque on teethScum in showerCause 80% of human infectionsUp to 1000x more resistantNo antibiotics, disinfectants or diagnostics approved for biofilmsInvolved in most cases of MRSA and hospital-acquired infections
The natural state of bacteria
Plaque on teeth
Scum in shower
Cause 80% of human infections
Up to 1000x more resistant
No antibiotics, disinfectants or diagnostics approved for biofilms
Involved in most cases of MRSA and hospital-acquired infections
Calcification Inhibitors in CKD and Dialysis Patients
Investor Presentation December 2010. 2 ... $2.2 $2.1 $1.9 • Largest P&C ... Data in both charts are for the year ended December 31, ...
www.intertek.com Investor Presentation: December 2010 2 Cautionary statement regarding ... Operating profit 2.0 11.1% Change Half Year 2010
Investor Presentation –December 2010. 2 December 2010 ... over 1 million forecast for 2010(1)
Investor Presentation December 2010. AMG ADVANCED METALLURGICAL GROUP N.V. 2 ... EPS of $0.42 (1) Net debt ...
Information is Presented Investor Presentation which Prepared to Inform the Investors
Investor PiPresentation December 2010. ... 2010 Subsidiaries Direct Indirect Total ... 7.1% asofSep. 2010.
Download Presentation >> December 1, 2011 . ... Download Presentation for Media >> December 15, 2010: ... Atos Global Homepage > Investors > Financial Calendar
Transportation and Industrials Conference ... Today’s presentation and discussion will ... 2009 Sept 30, 2010Sept 30, 2010 Cash On Hand $1.9 $10.9
for the year ended December 31, ... An article that compares the properties of InnovoSIL™-1 as an ... LLC 2010). Innovotech’s contract research ...